BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling.

The assessment of BRAF p.V600E mutational status has already become an essential part of the diagnostic routine in colorectal cancer (CRC). Indeed, on one side, the BRAF mutational status is regarded as being a key molecular marker to definitely decide the most proper therapeutic options in a selected cohort of patients. On the other, it is used to exclude a suspicious of Lynch Syndrome in case of MLH1 absence in deficient mismatch repair (dMMR) tumors [1]. This article is protected by copyright. All rights reserved.